Recombinant Macaca fascicularis PRA1 family protein 2 (PRAF2)

What is the basic structure and characteristics of PRAF2?

PRAF2 is a 19-kDa protein with four transmembrane-spanning domains that belongs to the PRAF protein family. The full-length Macaca fascicularis PRAF2 consists of 178 amino acids. Its structure features cytoplasmic extremities and transmembrane domains that are critical for its function as an ER-resident protein . The human PRAF2 gene is located on chromosome Xp11.23, and the protein is widely expressed in human tissues, with particularly high expression in the brain .

What is the amino acid sequence of recombinant Macaca fascicularis PRAF2?

The full amino acid sequence of recombinant Macaca fascicularis PRAF2 (1-178aa) is:
MSEVRLPPLRALDDFVLGSARLAAPDPCDPQRWCHRVINNLLYYQTNYLLCFGIGLALAG YVRPLHTLLSALVVAVALGMLVWAAETRAAVRRCRRSHPAACLAAVLAVGLLVLWVVGGA CTFLLSIAGPVLLILVHASLRLRNLKNKIENKIESIGLKRTPMGLLLEALGQEQEAGS

How is recombinant PRAF2 typically produced for research applications?

Recombinant PRAF2 for research applications is typically produced in E. coli expression systems with an N-terminal His tag to facilitate purification. The protein is generally supplied as a lyophilized powder and should be reconstituted in deionized sterile water to a concentration of 0.1-1.0 mg/mL. For long-term storage, it is recommended to add glycerol to a final concentration of 5-50% and aliquot for storage at -20°C/-80°C to avoid repeated freeze-thaw cycles .

What is the subcellular localization of PRAF2 and how can it be visualized?

PRAF2 primarily localizes to the endoplasmic reticulum (ER) as a resident protein with four transmembrane domains. In neuroblastoma cells, endogenous PRAF2 appears as bright cytoplasmic punctae when visualized by immunofluorescence microscopy . Researchers can visualize PRAF2 using specific antibodies for immunofluorescence staining or by generating tagged fusion proteins (such as PRAF2-YFP) for live-cell imaging in BRET (Bioluminescence Resonance Energy Transfer) or FRET-based assays .

What role does PRAF2 play in protein trafficking?

PRAF2 functions as a "gatekeeper" protein that regulates the cell-surface targeting of various transmembrane proteins. It can retain proteins in the ER on a stoichiometric basis, as demonstrated for the GB1 protomer of the GABA-B receptor, the cystic fibrosis transmembrane conductance regulator (CFTR), and the chemokine receptor CCR5 . For CCR5, PRAF2 inhibits plasma membrane export in a concentration-dependent manner, likely by preventing the receptor's recruitment into COPII vesicles at ER exit sites .

What methods can be used to study PRAF2's role in protein trafficking?

Researchers can employ several approaches to investigate PRAF2's function in protein trafficking:

• BRET-based subcellular localization systems to monitor protein transport to the cell surface

• Co-immunoprecipitation (Co-IP) to detect protein-protein interactions

• Proximity assays to determine interaction with specific transmembrane proteins

• Mutational analysis to identify critical domains for interaction

• Overexpression and knockdown studies to assess functional consequences

For example, BRET saturation curves generated by increasing concentrations of membrane markers (like GAP43-YFP) in the presence of constant amounts of receptor-Rluc fusion proteins can quantitatively measure cell surface expression levels and how they are affected by PRAF2 .

What is the correlation between PRAF2 expression and neuroblastoma progression?

High PRAF2 expression in neuroblastoma significantly correlates with several unfavorable clinical features:

These correlations suggest that PRAF2 may serve as a prognostic marker for neuroblastoma and potentially plays a role in disease progression .

What functional effects has PRAF2 been shown to have in cancer cells?

In cancer cells, PRAF2 has been demonstrated to have several functional effects:

• Promotion of cellular proliferation - shRNA-mediated PRAF2 downregulation in neuroblastoma cell lines results in decreased cellular proliferation

• Enhancement of migration - PRAF2 knockdown reduces cell migration capabilities

• Facilitation of matrix attachment - Loss of PRAF2 impairs matrix-attachment in neuroblastoma cells

• Support of colony formation - Loss of PRAF2 in HPV-16 cervical cancer cells reduces colony formation

• Association with metastasis - High PRAF2 expression correlates with bone and bone marrow metastasis in neuroblastoma patients

These findings collectively suggest that PRAF2 plays a role in promoting an aggressive cancer phenotype.

What are the recommended methods for studying PRAF2 function in cell culture models?

Several methodological approaches are effective for investigating PRAF2 function:

• RNA interference: shRNA-mediated PRAF2 downregulation can be used to assess its role in cellular proliferation, migration, and matrix-attachment .

• Overexpression studies: Transfection with PRAF2 expression vectors (with or without tags) can evaluate the effects of increased PRAF2 levels on cellular processes .

• Protein interaction studies:

  • Co-immunoprecipitation to identify binding partners

  • BRET-based proximity assays to study protein-protein interactions in living cells

  • Yeast two-hybrid screening to discover novel interactors

• Functional assays:

  • Proliferation assays (e.g., MTT, BrdU incorporation)

  • Migration assays (wound healing, transwell)

  • Colony formation assays

  • Apoptosis detection (Annexin V staining, PARP cleavage)

• Localization studies: Immunofluorescence microscopy with subcellular markers to determine precise localization and possible co-localization with interacting partners .

How can researchers effectively study PRAF2 expression in tissue samples?

For analyzing PRAF2 expression in tissue samples, researchers can employ:

• Transcriptomic analysis:

  • Microarray analysis (e.g., Affymetrix) to measure PRAF2 mRNA expression levels across different tumor types and compare with clinical parameters

  • RT-qPCR for targeted expression analysis in specific samples

• Protein detection:

  • Immunohistochemistry to visualize PRAF2 expression patterns in tissue sections

  • Western blotting to quantify protein levels in tissue lysates

  • Tissue microarrays for high-throughput analysis across multiple samples

• Correlation studies: Statistical analysis to determine associations between PRAF2 expression and clinical features (stage, survival, age at diagnosis, genetic alterations like MYCN amplification) .

What are the challenges in working with recombinant PRAF2 protein, and how can they be addressed?

Working with recombinant PRAF2 presents several challenges that researchers should address:

• Protein stability: PRAF2 is sensitive to repeated freeze-thaw cycles. Store working aliquots at 4°C for up to one week and avoid repeated freezing and thawing .

• Reconstitution protocol:

  • Briefly centrifuge the vial before opening

  • Reconstitute in deionized sterile water to 0.1-1.0 mg/mL

  • Add glycerol (final concentration 5-50%) for long-term storage

  • Aliquot for storage at -20°C/-80°C

• Transmembrane protein challenges: As a protein with four transmembrane domains, PRAF2 may be difficult to solubilize and maintain in its native conformation. Consider using appropriate detergents or membrane mimetics for functional studies.

• Functional assays: Because PRAF2 functions in protein trafficking and interactions with other membrane proteins, design assays that preserve the membrane environment or recreate it appropriately.

What are the known protein-protein interactions of PRAF2 and their functional significance?

PRAF2 has been demonstrated to interact with several proteins with important functional implications:

• CCR5 (chemokine receptor): PRAF2 inhibits the plasma membrane export of CCR5 in a concentration-dependent manner. This interaction involves the transmembrane domains of both proteins and affects CCR5 trafficking to the cell surface .

• GB1 (GABA-B receptor): PRAF2 functions as a gatekeeper for the GB1 protomer, interacting with a tandem di-leucine/RXR retention motif in the carboxyterminal tail .

• CFTR (cystic fibrosis transmembrane conductance regulator): PRAF2 can physiologically retain wild-type CFTR in the ER .

• HPV E5 protein: PRAF2 has been identified as a putative cellular binding partner of human papillomavirus (HPV) E5 oncoprotein, suggesting potential involvement in HPV-mediated carcinogenesis .

• Bcl-XL and Bcl-2: PRAF2 interacts with these anti-apoptotic proteins, potentially influencing cell survival pathways .

• GDE1/MIR16: PRAF2 interacts with human glycerophosphoinositol phosphodiesterase, which may be relevant to its cellular functions .

These interactions highlight PRAF2's diverse roles in membrane protein trafficking, viral pathogenesis, and cell survival pathways.

How does the interaction between PRAF2 and HPV E5 oncoprotein affect cellular processes?

The interaction between PRAF2 and HPV E5 appears to have significant implications for viral pathogenesis and cellular transformation:

• PRAF2 expression is elevated in HPV-16 cervical cancer cells and HPV-16 positive cervical cancer biopsies, suggesting a potential role in HPV-mediated carcinogenesis .

• Loss of PRAF2 in HPV-16 cervical cancer cells results in reduced colony formation and migration, indicating that PRAF2 may contribute to the oncogenic phenotype of HPV-infected cells .

• PRAF2 expression increases upon differentiation in normal human keratinocytes harboring either wild-type HPV-18 or E5 knockout genome, suggesting regulation during epithelial differentiation .

• PRAF2 overexpression reduces the thickness of stratified epithelium in HPV-18 rafts and causes loss of HPV-18 E1^E4 in E5 knockout rafts, suggesting that the E5-PRAF2 interaction is important to the viral lifecycle .

• Many proteins identified as putative PRAF2 cellular interactors have also been identified as putative HPV E5 protein interactors, suggesting potential coordinated effects on cellular pathways .

What is the relationship between PRAF2 and apoptotic pathways?

PRAF2 has shown complex relationships with apoptotic pathways:

• PRAF2 interacts with the anti-apoptotic proteins Bcl-XL and Bcl-2, suggesting a potential role in regulating cell survival pathways .

• PRAF2 protein levels increase in neuroblastoma cells undergoing cerulenin-induced apoptosis, indicating potential regulation during apoptotic processes .

• Studies investigating the proapoptotic function of PRAF2 in cervical cancer cells have yielded conflicting results, suggesting context-dependent effects on cell survival .

The dual role of PRAF2 in both promoting cancer cell proliferation and potentially regulating apoptosis suggests complex, context-dependent functions that warrant further investigation.

How might PRAF2's role in protein trafficking contribute to cancer progression?

PRAF2's role as a trafficking regulator may contribute to cancer progression through several mechanisms:

• Altered receptor density: By regulating the cell surface expression of receptors like CCR5, PRAF2 could modulate cellular responses to external signals that drive proliferation, migration, or survival .

• Disruption of normal protein homeostasis: Aberrant expression of PRAF2 in cancer cells may alter the normal balance of membrane proteins at the cell surface, potentially supporting oncogenic signaling pathways.

• Interaction with oncoproteins: The interaction with viral oncoproteins like HPV E5 suggests that PRAF2 may be co-opted during carcinogenesis to support viral functions or altered cellular signaling .

• Support of metastatic processes: The correlation between high PRAF2 expression and bone/bone marrow metastasis in neuroblastoma patients suggests a role in promoting cancer cell dissemination or colonization of distant sites .

Could PRAF2 serve as a therapeutic target for cancer treatment?

Based on current evidence, PRAF2 shows promise as a potential therapeutic target:

• Overexpression in multiple cancers: PRAF2 is overexpressed in various cancer types, including neuroblastoma, hepatocellular carcinoma, glioblastoma, breast, colon, lung, and ovarian cancers .

• Correlation with negative prognosis: High PRAF2 expression correlates with unfavorable clinical features in neuroblastoma, suggesting its importance in aggressive disease .

• Functional effects: Knockdown studies demonstrate that reducing PRAF2 can decrease proliferation, migration, and colony formation in cancer cells .

• Specific molecular interactions: The defined protein-protein interactions of PRAF2 could potentially be targeted with small molecule inhibitors or peptide mimetics.

• Differential expression: Higher expression in tumor tissues compared to normal tissues suggests potential for therapeutic selectivity .

Development of strategies to inhibit PRAF2 function or expression might provide novel therapeutic approaches, particularly for neuroblastoma and other cancers where PRAF2 is highly expressed.

What are the most promising research directions for understanding PRAF2 biology?

Several research directions hold promise for advancing our understanding of PRAF2 biology:

• Systems biology approaches: Comprehensive analysis of the PRAF2 interactome across different cell types and conditions to map its functional networks.

• Structural studies: Detailed structural analysis of PRAF2 and its complexes with interacting partners to facilitate rational drug design.

• In vivo models: Development of genetic models with PRAF2 manipulation to understand its role in development and disease progression.

• Mechanistic studies: Deeper investigation of how PRAF2 regulates protein trafficking at the molecular level and how this contributes to normal cellular function and disease states.

• Clinical correlations: Expanded analysis of PRAF2 expression across larger patient cohorts with detailed clinical annotation to refine its value as a biomarker.

• Therapeutic targeting: Exploration of approaches to modulate PRAF2 function or expression for potential therapeutic applications.